BioNexus Gene Revenue vs. Market Capitalization
| BGLC Stock | USD 0.23 0.01 4.17% |
Total Revenue | First Reported 2019-03-31 | Previous Quarter 2 M | Current Value 2.6 M | Quarterly Volatility 2.4 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.13 | 0.1361 |
|
|
For BioNexus Gene profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioNexus Gene to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioNexus Gene Lab utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioNexus Gene's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioNexus Gene Lab over time as well as its relative position and ranking within its peers.
BioNexus |
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.06) | Revenue Per Share 0.526 | Quarterly Revenue Growth (0.23) | Return On Assets (0.10) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioNexus Gene Lab Market Capitalization vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioNexus Gene's current stock value. Our valuation model uses many indicators to compare BioNexus Gene value to that of its competitors to determine the firm's financial worth. BioNexus Gene Lab is the top company in revenue category among its peers. It also is number one stock in market capitalization category among its peers creating about 0.44 of Market Capitalization per Revenue. The ratio of Revenue to Market Capitalization for BioNexus Gene Lab is roughly 2.27 . At present, BioNexus Gene's Total Revenue is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioNexus Gene's earnings, one of the primary drivers of an investment's value.BioNexus Revenue vs. Competition
BioNexus Gene Lab is the top company in revenue category among its peers. Market size based on revenue of Materials industry is currently estimated at about 16.12 Billion. BioNexus Gene adds roughly 9.77 Million in revenue claiming only tiny portion of all equities under Materials industry.
BioNexus Market Capitalization vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
BioNexus Gene |
| = | 9.77 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
BioNexus Gene |
| = | 4.31 M |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
BioNexus Market Capitalization vs Competition
BioNexus Gene Lab is number one stock in market capitalization category among its peers. Market capitalization of Materials industry is currently estimated at about 39.45 Billion. BioNexus Gene adds roughly 4.31 Million in market capitalization claiming only tiny portion of all equities under Materials industry.
BioNexus Gene Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioNexus Gene, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioNexus Gene will eventually generate negative long term returns. The profitability progress is the general direction of BioNexus Gene's change in net profit over the period of time. It can combine multiple indicators of BioNexus Gene, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -677.3 K | -643.4 K | |
| Net Income Applicable To Common Shares | 864.3 K | 907.5 K | |
| Income Tax Expense | 21.5 K | 20.4 K | |
| Operating Income | -2.6 M | -2.5 M | |
| Net Loss | -3.1 M | -2.9 M | |
| Income Before Tax | -2.6 M | -2.5 M | |
| Total Other Income Expense Net | -13.9 K | -13.2 K | |
| Net Loss | -2.6 M | -2.5 M | |
| Net Interest Income | -14.5 K | -15.2 K | |
| Non Operating Income Net Other | -210.6 K | -200 K | |
| Change To Netincome | 3.4 K | 3.6 K | |
| Net Loss | (0.17) | (0.16) | |
| Income Quality | 0.50 | 0.52 | |
| Net Income Per E B T | 1.01 | 0.70 |
BioNexus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioNexus Gene. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioNexus Gene position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioNexus Gene's important profitability drivers and their relationship over time.
Use BioNexus Gene in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNexus Gene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNexus Gene will appreciate offsetting losses from the drop in the long position's value.BioNexus Gene Pair Trading
BioNexus Gene Lab Pair Trading Analysis
The ability to find closely correlated positions to BioNexus Gene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNexus Gene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNexus Gene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNexus Gene Lab to buy it.
The correlation of BioNexus Gene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNexus Gene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNexus Gene Lab moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNexus Gene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BioNexus Gene position
In addition to having BioNexus Gene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Shipping Containers Thematic Idea Now
Shipping Containers
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Shipping Containers theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Shipping Containers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
To fully project BioNexus Gene's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioNexus Gene Lab at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioNexus Gene's income statement, its balance sheet, and the statement of cash flows.